RecruitingPhase 2NCT03629171

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

Studying Inherited acute myeloid leukemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Tapan M Kadia
M.D. Anderson Cancer Center
Intervention
Liposome-encapsulated Daunorubicin-Cytarabine(drug)
Enrollment
52 target
Eligibility
18 years · All sexes
Timeline
2018 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03629171 on ClinicalTrials.gov

Other trials for Inherited acute myeloid leukemia

Additional recruiting or active studies for the same condition.

See all trials for Inherited acute myeloid leukemia →

← Back to all trials